TRAIP antibody

E3 ubiquitin ligase acting as a negative regulator of innate immune signaling. Inhibits activation of NF-kappa-B mediated by TNF. Negatively regulates TLR3/4-and RIG-I-mediated IRF3 activation and subsequent IFNB1 production and cellular antiviral response by promoting 'Lys-48'-linked polyubiquitination of TNK1 leading to its proteasomal degradation (By similarity) (PubMed:22945920) . Involved in response to genotoxic lesions during genome replication. Promotes H2AX and RPA2 phosphorylation after replication-associated DNA damage and assists fork progression at UV-induced replication-blocking lesions during S phase (PubMed:26595769) . Has also been proposed to play a role in promoting translesion synthesis by mediating the assembly of 'Lys-63'-linked poly-ubiquitin chains on the Y-family polymerase POLN in order to facilitate bypass of DNA lesions and preserve genomic integrity (PubMed:24553286) . The function in translesion synthesis is controversial (PubMed:26595769) .

E3 ubiquitin-protein ligase TRAIP|RING finger protein 206|TRAF-interacting protein|TRAIP|RNF206|TRIP

10293

Q9BWF2

Human, Mouse

TRAF interacting protein

TRAIP

ELISA, WB, IHC, IF

Immunology, Signal Transduction

Immunogen affinity purified

WB: 1:500-1:2000; IHC: 1:20-1:200; IF: 1:10-1:100

≥95% as determined by SDS-PAGE

Liquid

53 kDa

PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20°C for 12 months (Avoid repeated freeze / thaw cycles.)

ELISA, WB, IHC, IF